Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Memantine and Antipsychotics Use (MemAP)

This study has been terminated.
(Study terminated due to too slow enrollment)
Sponsor:
Information provided by (Responsible Party):
Merz Pharmaceuticals GmbH
ClinicalTrials.gov Identifier:
NCT00649220
First received: March 27, 2008
Last updated: September 22, 2011
Last verified: September 2011

March 27, 2008
September 22, 2011
July 2008
May 2009   (final data collection date for primary outcome measure)
Maximum Dose Reduction of Antipsychotics (AP) in Percent of Defined Daily Dose (DDD) From Baseline to a Post-baseline Visit at Which the Value of the Visual Analogue Scale (VAS) Compared With the Baseline Value Was =< 15 Percent. [ Time Frame: Week 8-20 post baseline ] [ Designated as safety issue: No ]
VAS: see #8. Mean "percent of the total Defined Daily Dose (DDD)", averaged over one week, was calculated. Total DDD was calculated as sum of DDD for each AP drug. DDD is the assumed average maintenance dose per day defined by WHO. The reduction of AP Δ [percent] was calculated as a difference between the mean total DDD recorded at baseline and the mean total DDD recorded at the respective week. Measurements from those post-baseline visits were taken into account only when the value of the VAS was not substantially worse compared to baseline.
The primary endpoint is the maximum dose reduction of antipsychotics from baseline to a post-baseline visit without significant behavioral change. [ Time Frame: at post-baseline visit ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00649220 on ClinicalTrials.gov Archive Site
  • Reduction of Antipsychotic Drug Dose From Baseline to Week 8, 12, 16 and/or 20. [ Time Frame: Week 8-20 post Baseline ] [ Designated as safety issue: No ]
    See #1 and #8. Change of <0 reveals a reduction of AP compared to baseline.
  • Change in the Mini-Mental State Examination (MMSE) Score Value From Baseline to Week 20. [ Time Frame: Week 20 post baseline ] [ Designated as safety issue: No ]
    MMSE is a brief, physician-administered scale, designed for measuring the cognitive functions, such as: orientation, memory, attention, naming, and comprehension. The scoring range of MMSE is 0 to 30 points. A score of 23 or lower is indicative of cognitive impairment. Change of >0 reveals an improvement compared to baseline.
  • Change of "Test for the Early Detection of Dementia With Discrimination From Depression [TE4D]" Score Value From Baseline to Week 4, 8, 12, 16, and/or 20 - First Part: Total Dementia [ Time Frame: Week 4-20 post baseline ] [ Designated as safety issue: No ]

    TE4D is a psychometric, physician-administered test that is used for both screening subjects with early dementia and monitoring the clinical progress of the disease. The first part consists of 9 items, which assess different symptoms associated with dementia such as memory, time-orientation, etc. The scoring range is 0 to 50 points. A score of 35 or lower is an indication of dementia.

    A change >0 represents an improvement.

  • Change of "Test for the Early Detection of Dementia With Discrimination From Depression [TE4D]" Score Value From Baseline to Week 4, 8, 12, 16, and/or 20 - Second Part: Total Depression [ Time Frame: Week 4-20 post Baseline ] [ Designated as safety issue: No ]

    TE4D is a psychometric, physician-administered test that is used for both screening subjects with early dementia and monitoring the clinical progress of the disease. The second part consists of a proxy rating and a self-assessment rating. The scoring range of each rating is 1 to 10. The maximum total score of 10 corresponds to severe depression.

    A change <0 reveals an improvement compared to baseline.

  • Change of Modified Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADLB19) Score Value From Baseline to Week 4, 8, 12, 16, and/or 20. [ Time Frame: Week 4-20 post Baseline ] [ Designated as safety issue: No ]

    The modified ADCS-ADL19 is comprehensive battery of ADL questions aimed to measure the functional ability of subjects with Dementia of Alzheimer's type over a broad range of dementia severity. It has a scoring range of 0 to 54 with the lower scores indicating greater functional impairment. Each ADL item was rated from the highest level of independent performance to complete loss.

    Change of >0 reveals an improvement compared to baseline.

  • Change of Nurses' Observation Scale for Geriatric Patients [NOSGER] Total Score Value From Baseline to Week 4, 8, 12, 16, and/or 20 [ Time Frame: Week 4-20 post Baseline ] [ Designated as safety issue: No ]

    NOSGER is a comprehensive scale, which contains 30 items of behavior, each rated on a 5-point scale according to the frequency of occurrence by direct observation. Item scores are summarized into 6 dimension scores: memory, instrumental activities of daily life, self-care, mood, social behavior, and disturbing behavior. The NOSGER has a scoring range of 30 to 150 with the higher scores indicating worse subject's status. The items in each group are rated for their frequency ranging from 1 (never) to 5 (always).

    A change of <0 reveals an improvement compared to baseline.

  • Change in the VAS Score From Baseline to Week 8, 12, 16 and/or 20. [ Time Frame: Week 8-20 post Baseline ] [ Designated as safety issue: No ]
    VAS is a report device to measure the subject's burden caused by behavioral symptoms. To measure the burden on the VAS only the first 3 items of the Neuropsychiatric Inventory (NPI) Questionnaire were considered (delusions, hallucinations (visual and auditory), and agitation / aggression). The VAS consists of a 100 mm horizontal line, anchored at the ends with the reference "not at all" and "extremely". The VAS score was determined by measuring in mm from the left hand end of the line to the point, where the investigator had marked the magnitude of a subject's burden.
The secondary parameter assesses behavior from baseline to a post-baseline visit. [ Time Frame: at post-baseline visit ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Memantine and Antipsychotics Use
Prospective, Single-arm, Multi-centre, Open-label Study to Investigate the Potential to Reduce Concomitant Antipsychotics Use in Patients With Moderate to Severe Dementia of Alzheimer's Type (DAT) Treated With Memantine

To investigate the potential to reduce concomitant antipsychotic medication use in subjects with moderate dementia of Alzheimer's type, treated with memantine.

Not Provided
Interventional
Phase 4
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Alzheimer's Disease
Drug: Memantine
memantine tablets, twice a day (bid), for 20 weeks
Experimental: Memantine
Intervention: Drug: Memantine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
19
June 2009
May 2009   (final data collection date for primary outcome measure)

Inclusion criteria:

  • Current diagnosis of probable Alzheimer's disease consistent with NINCDS-ADRDA criteria or with DSM IV TR criteria for Dementia of the Alzheimer's type.
  • MRI or CT scan supporting the diagnosis of DAT without indications of any relevant other CNS disorders.
  • Patients treated with any acetylcholinesterase inhibitor (AChEI) man be included.
  • The patient should have German as a mother-tongue or at least speak the language fluently.

Exclusion criteria:

  • Evidence (including CT/MRI results) of any clinically significant central nervous system disease other than Alzheimer's disease.
  • Modified Hachinski Ischemia score greater than 4 at screening.
  • Intake of any medication that is contra-indicated in combination with memantine.
  • Treatment with depot antipsychotics.
  • History of severe drug allergy, or hypersensitivity, or patients with known hypersensitivity to memantine, amantadine or lactose.
  • Known or suspected history of alcoholism or drug abuse within the past 10 years.
  • Previous treatment with memantine or participation in an investigational study with memantine.
Both
50 Years to 85 Years
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT00649220
MRZ 90001-0716/1, 2007-004489-41
No
Merz Pharmaceuticals GmbH
Merz Pharmaceuticals GmbH
Not Provided
Study Director: Medical Expert Merz Pharmaceuticals GmbH
Merz Pharmaceuticals GmbH
September 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP